In a phase I/II study conducted in children with R/R B-ALL, blinatumomab, a bispecific T-cell engager antibody targeting CD19, was able to induce cytomorphological remission in 39% of subjects, which was MRD-negative in 52% of cases [137]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.